FDA Approves New TB Drug

Sirturo is the first drug approved to treat multi-drug resistant TB. It works by inhibiting an enzyme needed by M. tuberculosis to replicate and spread throughout the body.

The U.S. Food and Drug Administration announced Dec. 31 it has approved Sirturo (bedaquiline) as part of combination therapy to treat adults with multi-drug resistant pulmonary tuberculosis when alternatives are not available.

TB is an infection caused by Mycobacterium tuberculosis; CDC reports nearly 9 million people around the world and 10,528 people in the United States became sick with TB during 2011. Multi-drug resistant TB occurs when M. tuberculosis becomes resistant to isonazid and rifampin, the drugs most commonly used to treat TB. Sirturo is the first drug approved to treat multi-drug resistant TB and works by inhibiting an enzyme needed by M. tuberculosis to replicate and spread throughout the body.

"Multi-drug resistant tuberculosis poses a serious health threat throughout the world, and Sirturo provides much-needed treatment for patients who have don't have other therapeutic options available," said Edward Cox, M.D., MPH, director of the Office of Antimicrobial Products in FDA's Center for Drug Evaluation and Research. "However, because the drug also carries some significant risks, doctors should make sure they use it appropriately and only in patients who don't have other treatment options."

Sirturo is being approved under FDA's accelerated approval program, which allows for earlier access to promising new drugs while the companies conduct additional studies to confirm their clinical benefit and safe use. FDA also granted Sirturo fast track designation, priority review, and orphan-product designation. "The drug demonstrated the potential to fill an unmet medical need, has the potential to provide safe and effective treatment where no satisfactory alternative therapy exists, and is intended to treat a rare disease, respectively," according to the agency's news release.

Sirturo's manufacturer, Janssen Therapeutics, is a division of Janssen Products LP and is based in Titusville, N.J.

Download Center

  • EHS Buyer's Guide

    Download this buyer's guide to make more informed decisions as you're looking for an EHS management software system for your organization.

  • Online Safety Training Buyer's Guide

    Use this handy buyer's guide to learn the basics of selecting online safety training and how to use it at your workplace.

  • COVID Return-to-Work Checklist, Fall 2021

    Use this checklist as an aid to help your organization return to work during the COVID-19 pandemic in a safe and healthy manner.

  • SDS Buyer's Guide

    Learn to make informed decisions while searching for SDS Management Software.

  • Risk Matrix Guide

    Risk matrices come in many different shapes and sizes. Understanding the components of a risk matrix will allow you and your organization to manage risk effectively.

  • Industry Safe

Featured Whitepapers

OH&S Digital Edition

  • OHS Magazine Digital Edition - September 2021

    September 2021

    Featuring:

    • COMBUSTIBLE DUST
      Managing Combustible Dust and Risk Mitigation
    • PPE: CONSTRUCTION
      The Rising Popularity of Safety Helmets on the Jobsite
    • PPE: ELECTRICAL SAFETY
      Five Tips for a Successful Wear Trial
    • SAFETY & HEALTH
      Medical Surveillance Versus Medical Screening
    View This Issue